Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer

The use of molecularly targeted therapies has markedly improved the survival of patients with non-small cell lung cancer (NSCLC) harboring specific oncogenic alterations, such as epidermal growth factor (EGFR) mutations, anaplastic lymphoma kinase (ALK) and ROS1 rearrangements. Hence, molecular profiling of tumors has been rapidly incorporated into clinical practice in order to define the optimal therapeutic strategy (1).